Home self-administration of omalizumab for chronic spontaneous urticaria

Br J Dermatol. 2016 Dec;175(6):1405-1407. doi: 10.1111/bjd.15074. Epub 2016 Oct 27.

Authors

S Denman¹, K Ford¹, J Toolan¹, A Mistry¹, C Corps¹, P Wood¹, S Savic^{1

2}

Affiliations

¹ Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, U.K.
² National Institute for Health Research-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James's University Hospital, Beckett Street, Leeds, U.K.

PMID: 27639259
DOI: 10.1111/bjd.15074

No abstract available

Publication types

Letter

MeSH terms

Anti-Allergic Agents / therapeutic use*
Chronic Disease
Cost-Benefit Analysis
Humans
Omalizumab / therapeutic use*
Self Administration
Treatment Outcome
Urticaria / drug therapy*

Substances

Anti-Allergic Agents
Omalizumab